Simplification of complex insulin regimens using canagliflozin or liraglutide in patients with well-controlled type 2 diabetes: A 24-week randomized controlled trial.

Ando Y, Shigiyama F, Hirose T, Kumashiro N

Journal of diabetes investigation18 Mar 2021Cited by 13 (Europe PMC)

PMID33650779PMCIDPMC8504902DOI10.1111/jdi.13533PepBankPUB-33650779

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with well-controlled type 2 diabetes on multiple daily insulin injections, the change in HbA1c with liraglutide in place of bolus insulin was comparable to that with canagliflozin.
In plain wordsIn adults with well-controlled type 2 diabetes, liraglutide and canagliflozin changed HbA1c by a similar amount when each replaced mealtime insulin.
Peptide
Liraglutide
Outcome
No significant changeHbA1c change versus canagliflozin
Study
n = 40
Comparator
Canagliflozin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.3-0.9 mg/day · 24 weeksAs given in this study (human).
Source sentences
Summary
The change in HbA1c from baseline was comparable between the treatments.
1 context sentence(design, population, supporting numbers)
Summary · context
In 40 patients, with glycated hemoglobin (HbA1c) levels <7.5% controlled by multiple daily insulin injection therapy, all bolus insulin was randomly switched to canagliflozin (100 mg/day) or liraglutide (0.3-0.9 mg/day) for 24 weeks.
Report a problemFND-3365077901
02HumanRandomized controlled trialEfficacy outcome
In adults with well-controlled type 2 diabetes, replacing bolus insulin with liraglutide maintained HbA1c at baseline levels for 24 weeks.
In plain wordsIn adults with well-controlled type 2 diabetes, HbA1c stayed at its starting level for 24 weeks when liraglutide replaced mealtime insulin.
Peptide
Liraglutide
Outcome
No significant changeHbA1c maintained from baseline
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.3-0.9 mg/day · 24 weeksAs given in this study (human).
Source sentences
Summary
Both treatments maintained the HbA1c level to the baseline levels with stable glucose variability and no severe hypoglycemia for 24 weeks, decreased total insulin dose, and significantly increased the QOL score.
1 context sentence(design, population, supporting numbers)
Summary · context
In 40 patients, with glycated hemoglobin (HbA1c) levels <7.5% controlled by multiple daily insulin injection therapy, all bolus insulin was randomly switched to canagliflozin (100 mg/day) or liraglutide (0.3-0.9 mg/day) for 24 weeks.
Report a problemFND-3365077902
03HumanRandomized controlled trialEfficacy outcome
In adults with well-controlled type 2 diabetes, glucose variability stayed stable when liraglutide replaced bolus insulin.
In plain wordsIn adults with well-controlled type 2 diabetes, swings in blood sugar stayed stable when liraglutide replaced mealtime insulin.
Peptide
Liraglutide
Outcome
No significant changeGlucose variability by continuous glucose monitoring
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.3-0.9 mg/day · 24 weeksAs given in this study (human).
Source sentences
Summary
Both treatments maintained the HbA1c level to the baseline levels with stable glucose variability and no severe hypoglycemia for 24 weeks, decreased total insulin dose, and significantly increased the QOL score.
1 context sentence(design, population, supporting numbers)
Summary · context
In 40 patients, with glycated hemoglobin (HbA1c) levels <7.5% controlled by multiple daily insulin injection therapy, all bolus insulin was randomly switched to canagliflozin (100 mg/day) or liraglutide (0.3-0.9 mg/day) for 24 weeks.
Report a problemFND-3365077903
04HumanRandomized controlled trialSafety outcome
In adults with well-controlled type 2 diabetes, there was no severe hypoglycemia for 24 weeks when liraglutide replaced bolus insulin.
In plain wordsIn adults with well-controlled type 2 diabetes, no severe low blood sugar happened when liraglutide replaced mealtime insulin.
Peptide
Liraglutide
Outcome
No significant changeSevere hypoglycemia
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Studied dose
0.3-0.9 mg/day · 24 weeksAs given in this study (human).
Source sentences
Summary
Both treatments maintained the HbA1c level to the baseline levels with stable glucose variability and no severe hypoglycemia for 24 weeks, decreased total insulin dose, and significantly increased the QOL score.
1 context sentence(design, population, supporting numbers)
Summary · context
In 40 patients, with glycated hemoglobin (HbA1c) levels <7.5% controlled by multiple daily insulin injection therapy, all bolus insulin was randomly switched to canagliflozin (100 mg/day) or liraglutide (0.3-0.9 mg/day) for 24 weeks.
Report a problemFND-3365077904
05HumanRandomized controlled trialEfficacy outcome
In adults with well-controlled type 2 diabetes, total insulin dose decreased when liraglutide replaced bolus insulin.
In plain wordsIn adults with well-controlled type 2 diabetes, the total insulin dose went down when liraglutide replaced mealtime insulin.
Peptide
Liraglutide
Outcome
DecreaseTotal insulin dose
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.3-0.9 mg/day · 24 weeksAs given in this study (human).
Source sentences
Summary
Both treatments maintained the HbA1c level to the baseline levels with stable glucose variability and no severe hypoglycemia for 24 weeks, decreased total insulin dose, and significantly increased the QOL score.
1 context sentence(design, population, supporting numbers)
Summary · context
In 40 patients, with glycated hemoglobin (HbA1c) levels <7.5% controlled by multiple daily insulin injection therapy, all bolus insulin was randomly switched to canagliflozin (100 mg/day) or liraglutide (0.3-0.9 mg/day) for 24 weeks.
Report a problemFND-3365077905
06HumanRandomized controlled trialEfficacy outcome
In adults with well-controlled type 2 diabetes, the quality of life score increased significantly when liraglutide replaced bolus insulin.
In plain wordsIn adults with well-controlled type 2 diabetes, quality of life improved when liraglutide replaced mealtime insulin.
Peptide
Liraglutide
Outcome
IncreaseQuality of life score
Study
n: not reported in source
Outcome group
Quality of life · Whole body
Studied dose
0.3-0.9 mg/day · 24 weeksAs given in this study (human).
Source sentences
Summary
Both treatments maintained the HbA1c level to the baseline levels with stable glucose variability and no severe hypoglycemia for 24 weeks, decreased total insulin dose, and significantly increased the QOL score.
1 context sentence(design, population, supporting numbers)
Summary · context
In 40 patients, with glycated hemoglobin (HbA1c) levels <7.5% controlled by multiple daily insulin injection therapy, all bolus insulin was randomly switched to canagliflozin (100 mg/day) or liraglutide (0.3-0.9 mg/day) for 24 weeks.
Report a problemFND-3365077906

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

07HumanNot a test of Liraglutide aloneRandomized controlled trialOther
In adults with type 2 diabetes in this trial, the change in quality of life was significantly associated with injection frequency.
In plain wordsIn adults with type 2 diabetes, quality of life changed with the number of injections, across both treatments.
Peptide
Liraglutide
Outcome
Not applicableAssociation of change in quality of life with injection frequency
Study
n = 40
Outcome group
Quality of life · Whole body
Source sentences
Summary
The change in QOL was significantly associated with injection frequency.
1 context sentence(design, population, supporting numbers)
Summary · context
In 40 patients, with glycated hemoglobin (HbA1c) levels <7.5% controlled by multiple daily insulin injection therapy, all bolus insulin was randomly switched to canagliflozin (100 mg/day) or liraglutide (0.3-0.9 mg/day) for 24 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3365077907

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.